Go Pro
→ The rich already moved their money (From Parkview Capital Group) (Ad)tc pixel Free TGTX Stock Alerts

TG Therapeutics (TGTX) Competitors

TG Therapeutics logo
$53.90 +0.28 (+0.52%)
As of 12:24 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

TGTX vs. ALNY, BIIB, ROIV, INSM, and INCY

Should you buy TG Therapeutics stock or one of its competitors? TG Therapeutics's main competitors and comparable companies include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Roivant Sciences (ROIV), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TG Therapeutics compare to Alnylam Pharmaceuticals?

TG Therapeutics (NASDAQ:TGTX) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 16.88%. Alnylam Pharmaceuticals has a consensus target price of $366.90, suggesting a potential upside of 65.38%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Alnylam Pharmaceuticals is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Alnylam Pharmaceuticals
0 Sell rating(s)
6 Hold rating(s)
16 Buy rating(s)
2 Strong Buy rating(s)
2.83

In the previous week, Alnylam Pharmaceuticals had 3 more articles in the media than TG Therapeutics. MarketBeat recorded 7 mentions for Alnylam Pharmaceuticals and 4 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.26 beat Alnylam Pharmaceuticals' score of 0.19 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alnylam Pharmaceuticals
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

TG Therapeutics has a net margin of 55.22% compared to Alnylam Pharmaceuticals' net margin of 15.26%. Alnylam Pharmaceuticals' return on equity of 84.93% beat TG Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics55.22% 73.49% 34.14%
Alnylam Pharmaceuticals 15.26%84.93%14.30%

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

TG Therapeutics has higher earnings, but lower revenue than Alnylam Pharmaceuticals. TG Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M13.39$447.18M$2.7419.67
Alnylam Pharmaceuticals$3.71B7.99$313.75M$5.3841.24

TG Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

Summary

Alnylam Pharmaceuticals beats TG Therapeutics on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Biogen has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.29$1.29B$5.6538.99
TG Therapeutics$616.29M13.39$447.18M$2.7419.67

Biogen presently has a consensus price target of $230.14, suggesting a potential upside of 4.46%. TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 16.88%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
13 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
2.56
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44

87.9% of Biogen shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

TG Therapeutics has a net margin of 55.22% compared to Biogen's net margin of 8.32%. TG Therapeutics' return on equity of 73.49% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen8.32% 11.18% 6.88%
TG Therapeutics 55.22%73.49%34.14%

In the previous week, Biogen had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 8 mentions for Biogen and 4 mentions for TG Therapeutics. Biogen's average media sentiment score of 1.02 beat TG Therapeutics' score of 0.26 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
4 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Biogen beats TG Therapeutics on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

TG Therapeutics (NASDAQ:TGTX) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

TG Therapeutics has a net margin of 55.22% compared to Roivant Sciences' net margin of -3,534.96%. TG Therapeutics' return on equity of 73.49% beat Roivant Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics55.22% 73.49% 34.14%
Roivant Sciences -3,534.96%-22.94%-21.53%

TG Therapeutics has a beta of 1.8, meaning that its share price is 80% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

TG Therapeutics currently has a consensus target price of $63.00, indicating a potential upside of 16.88%. Roivant Sciences has a consensus target price of $45.64, indicating a potential upside of 28.50%. Given Roivant Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Roivant Sciences is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Roivant Sciences
1 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.85

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 8.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M13.39$447.18M$2.7419.67
Roivant Sciences$8.26M3,105.63-$299.77M-$0.53N/A

In the previous week, TG Therapeutics had 1 more articles in the media than Roivant Sciences. MarketBeat recorded 4 mentions for TG Therapeutics and 3 mentions for Roivant Sciences. TG Therapeutics' average media sentiment score of 0.26 beat Roivant Sciences' score of -0.54 indicating that TG Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Roivant Sciences
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Negative

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, risk, earnings, profitability, dividends, valuation and analyst recommendations.

Insmed presently has a consensus target price of $200.57, indicating a potential upside of 85.02%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 16.88%. Given Insmed's stronger consensus rating and higher probable upside, analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Insmed
1 Sell rating(s)
0 Hold rating(s)
22 Buy rating(s)
2 Strong Buy rating(s)
3.00
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44

Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Insmed's net margin of -76.94%. TG Therapeutics' return on equity of 73.49% beat Insmed's return on equity.

Company Net Margins Return on Equity Return on Assets
Insmed-76.94% -123.94% -44.30%
TG Therapeutics 55.22%73.49%34.14%

TG Therapeutics has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Insmed$606.42M39.04-$1.28B-$4.11N/A
TG Therapeutics$616.29M13.39$447.18M$2.7419.67

58.6% of TG Therapeutics shares are owned by institutional investors. 2.1% of Insmed shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Insmed had 1 more articles in the media than TG Therapeutics. MarketBeat recorded 5 mentions for Insmed and 4 mentions for TG Therapeutics. Insmed's average media sentiment score of 0.59 beat TG Therapeutics' score of 0.26 indicating that Insmed is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Insmed
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

TG Therapeutics beats Insmed on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Incyte?

TG Therapeutics (NASDAQ:TGTX) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

TG Therapeutics has a net margin of 55.22% compared to Incyte's net margin of 27.71%. TG Therapeutics' return on equity of 73.49% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics55.22% 73.49% 34.14%
Incyte 27.71%29.93%22.88%

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M13.39$447.18M$2.7419.67
Incyte$5.14B4.57$1.29B$7.8514.75

TG Therapeutics currently has a consensus price target of $63.00, suggesting a potential upside of 16.88%. Incyte has a consensus price target of $126.15, suggesting a potential upside of 8.92%. Given TG Therapeutics' higher possible upside, equities research analysts plainly believe TG Therapeutics is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Incyte
0 Sell rating(s)
12 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.56

In the previous week, Incyte had 19 more articles in the media than TG Therapeutics. MarketBeat recorded 23 mentions for Incyte and 4 mentions for TG Therapeutics. Incyte's average media sentiment score of 0.62 beat TG Therapeutics' score of 0.26 indicating that Incyte is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Incyte
7 Very Positive mention(s)
4 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

TG Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market. Comparatively, Incyte has a beta of 0.74, suggesting that its stock price is 26% less volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Incyte beats TG Therapeutics on 10 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TGTX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TGTX vs. The Competition

Export
MetricTG TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$8.22B$3.84B$7.12B$13.24B
Dividend YieldN/A3.64%2.53%15.88%
P/E Ratio19.5913.57274.2126.08
Price / Sales13.391,293.43607.9392.41
Price / Cash19.91121.7677.3851.25
Price / Book13.2116.7410.926.30
Net Income$447.18M-$22.67M$3.50B$361.41M
7 Day Performance-6.15%-2.77%-2.09%-1.55%
1 Month Performance-5.27%-10.47%-6.33%-3.80%
1 Year Performance47.03%21.88%9.10%2.92%

TG Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TGTX
TG Therapeutics
3.4101 of 5 stars		$53.90
+0.5%		$63.00
+16.9%		+46.7%$8.22B$616.29M19.59399
ALNY
Alnylam Pharmaceuticals
3.9168 of 5 stars		$244.32
+2.0%		$367.20
+50.3%		-49.8%$32.06B$3.71B45.412,770
BIIB
Biogen
2.8098 of 5 stars		$219.07
+1.7%		$230.14
+5.1%		+44.5%$31.84B$9.89B38.777,500
ROIV
Roivant Sciences
2.6368 of 5 stars		$38.99
-2.0%		$45.64
+17.0%		+125.4%$28.73B$8.26MN/A721
INSM
Insmed
3.6153 of 5 stars		$121.00
+0.8%		$204.91
+69.3%		-26.3%$26.21B$606.42MN/A1,664

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
The SEC Just Opened The Floodgates…
The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...
StocksToTrade | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The "velvet rope" stock setups hiding from regular indicators
K.I.R.A. is a new trading engine built to flag market setups before they show up on standard charts. Former...
The TradingPub | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel
"How Much Can I Actually Spend Each Year With $2.5M Saved?"
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...
SmartAsset | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel